Viveve (VIVE) Fair Value & Analysis
Healthcare · US · Market cap $2.1K
Viveve
VIVE · US
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 5 days ago
Fair value updated Jun 26, 2026 — revised from $6.32 to $0.0002 (−100.0%) since Jun 25, 2026.
Price vs Fair Value (12 months)
12‑month range $0.0001 – $0.0009 · fair‑value band $0.0002 – $0.0002 · the $0.0002 price screens below the $0.0002 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Viveve (VIVE) currently trades at $0.0002, while our model-based Fair Value estimate is $0.0002 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 89/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at $6.8M. Revenue grew 4.2% year over year. The balance sheet holds a net cash position of $13.8M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Viveve develops and sells healthcare-focused human resources (HR) software solutions designed to streamline and unify HR operations for healthcare organizations. It offers an all-in-one platform that supports recruitment, employee management, and attendance management, aiming to reduce administrative burden and enhance the employee experience throughout their career lifecycle. The company also provides solutions specifically tailored for the healthcare and mental and behavioral health sectors. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.
Revenue & earnings trend
FY2017 – FY2021 · reported fiscal years
Viveve reported revenue of $6.4M in FY2021 versus $15.3M in FY2017, a compound −19.5%/yr. Reported net income was −$22.0M in FY2021.
Is VIVE fairly valued? → Check now
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| ABT ABT | 1,600 MXN | 1,228 MXN | -23% |
| Abbott Laboratories, ABTT34 | R$38.22 | R$30.39 | -20% |
| Stryker Corporation S1YK34 | R$79.21 | R$43.74 | -45% |
| Medtronic plc MDT | $81.67 | $60.02 | -27% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.98 | $41.02 | -52% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Viveve (VIVE) undervalued?
What is the fair value of VIVE?
What is the quality score of VIVE?
What is the revenue of Viveve (VIVE)?
What is the net profit margin of VIVE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.